1
Kevin P Anderson, Ronnie C Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furusako, Thomas W Bruice, Walter F Lima: Compositions and methods for treatment of Hepatitis C virus-associated diseases. Isis Pharmaceuticals, Licata & Tyrell P C, July 23, 2002: US06423489 (56 worldwide citation)

Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These c ...


2
Kevin P Anderson, Ronnie C Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furasako, Thomas W Bruice, Walter F Lima: Compositions and methods for treatment of Hepatitis C virus-associated diseases. Isis Pharmaceuticals, Licata & Tyrrell P C, May 21, 2002: US06391542 (42 worldwide citation)

Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These c ...


3
Kevin P Anderson, Ronnie C Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa: Compositions and methods for treatment of hepatitis C virus-associated diseases. Isis Pharmaceuticals, Licata & Tyrrell P C, September 4, 2001: US06284458 (31 worldwide citation)

Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These c ...


4
Hiroshi Nakatake, Masaru Fuku, Tatsuya Okuda, Yoshikazu Tsunoda: Gate driving circuit. Mitsubishi Electric Corporation, Oblon Spivak McClelland Maier & Neustadt L, April 23, 2013: US08427225 (4 worldwide citation)

To obtain a gate driving circuit in which rising of a constant current of a constant current circuit is fast and power saving is achieved, the gate driving circuit includes: a constant current driving circuit (28) for supplying a constant current; a gate terminal of a power semiconductor element (1) ...


5
Chikateru Nozaki, Hiroshi Nakatake, Yoichiro Kino, Tatsuo Eto, Keiichi Makizumi, Nobuya Ohtomo: Recombinant plasmid inserted with herpes simplex virus gene. Juridical Foundation The Chemo Sero Therapeutic Research Institute, Wegner Cantor Mueller & Player, October 22, 1991: US05059538 (4 worldwide citation)

A novel recombinant plasmid inserted with a herpes simplex virus gene, which comprises a plasmid vector containing a yeast DNA sequence and an Escherichia coli DNA sequence and carrying a promoter region and a herpes simplex virus gN gene (HSVgB) gene) recombined thereto under control of the promote ...


6
Hiroshi Nakatake, Satoshi Ishibashi, Shinsuke Idenoue, Takeshi Oi, Shinichi Kinouchi, Takeshi Horiguchi: Drive circuit for semiconductor element. Mitsubishi Electric Corporation, Oblon Spivak McClelland Maier & Neustadt L, May 24, 2011: US07948277 (2 worldwide citation)

A drive circuit wherein any abnormality of a semiconductor element is prevented from being erroneously sensed in a case where a gate “ON” command has entered in a state in which a gate voltage of the semiconductor element has not lowered fully. A detection process for a controlled variable of the se ...


7
Hiroshi Nakatake, Shinichi Kinouchi, Tatsuya Kitamura: Gate driving circuit. Mitsubishi Electric Corporation, Oblon Spivak McClelland Maier & Neustadt L, December 3, 2013: US08598920 (2 worldwide citation)

A gate driving circuit for driving a voltage-driven switching device is provided with a current limiting circuit for limiting a gate current ig that flows into a gate terminal through a gate resistor at turn-on to a current limit value IL which defines an upper limit value. The current limit value I ...


8
Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo: Recombinant factor X with no glycosylation and method for preparing the same. Juridical Foundation The Chemo Sero Therapeutic Research Institute, Oblon Spivak McClelland Maier & Neustadt L, October 23, 2012: US08293874 (1 worldwide citation)

A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby ...


9
Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo: Recombinant Factor X with no glycosylation and method for preparing the same. Juridical Foundation the Chemo Sero Therapeutic Research Institute, Oblon Spivak McClelland Maier & Neustadt L, May 8, 2012: US08173777 (1 worldwide citation)

A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby ...


10
Yoshiko Obiraki, Yasushi Nakayama, Yuji Miyazaki, Hiroshi Nakatake: Power semiconductor module and power conversion device. Mitsubishi Electric Corporation, Oblon McClelland Maier & Neustadt L, May 22, 2018: US09979314

A power semiconductor module capable of reducing variation of inductance between upper/lower arms and reducing variation of current caused by the variation of inductance. The power semiconductor module includes circuit blocks (upper/lower arms) each of which is configured by connecting self-arc-exti ...